Novartis

Novartis gets USFDA nod for its therapy to treat Berger’s disease

IgAN is a progressive, rare kidney disease in which the immune system attacks the kidneys, often causing glomerular inflammation and…

April 3, 2025 11:19 IST

Novartis’ novel therapy to treat SMA Type 2 shows significant positive outcome in Phase III study

The results from the Phase III STEER study add to the clinical data and emerging real-world evidence for the use…

December 31, 2024 12:58 IST

European Commission gives nod to Novartis’ novel therapy to treat breast cancer

Following recent data announcements at ESMO 20246, Novartis will continue to evaluate NATALEE patients for longer-term outcomes, including overall survival,…

November 27, 2024 16:13 IST

Novartis highlights deep pipeline in core therapeutic areas to drive long-term growth, upgrades mid-term guidance

The company remains on track to deliver core operating income margin of 40%+ by 2027, benefiting from continued strong sales…

November 22, 2024 13:07 IST

Novartis gets positive CHMP opinion for its breast cancer drug to reduce risk of recurrence

According to Novartis, the positive CHMP decision is based on robust data from the Phase III NATALEE trial.

October 18, 2024 18:08 IST

Novartis’ cholesterol-lowering drug shows positive outcome in Phase III trial

Novartis plans to present results from this trial at an upcoming medical meeting and share them with regulatory agencies including…

August 28, 2024 12:39 IST

Novartis releases Phase III data on its investigational oral therapy to treat chronic kidney disease

Atrasentan has the potential to help transform how IgAN is managed for many people living with this complex illness, the…

May 27, 2024 10:58 IST

Novartis to acquire nearly 12 percent stake of MorphoSys AG

Novartis continues to progress the workstreams for implementation of both a delisting of MorphoSys and a domination and profit and…

May 16, 2024 17:34 IST

USFDA gives nod to Novartis’ therapy for rare cancer among children

The study reported a safety profile consistent with the adult population studied in NETTER-1, the pivotal trial for approval of…

April 25, 2024 14:13 IST

Novartis’ Multiple Sclerosis drug is effective for up to six years, study reveals

Multiple Sclerosis is a disease in which the immune system damages the protective covering of nerves. In this condition, nerve…

April 19, 2024 16:02 IST

Novartis releases data of its investigational drug showing positive outcome in Phase 3 trial

Novartis will be presenting further data from the renal portfolio at future medical meetings, it added.

April 16, 2024 13:19 IST

Novartis enters into licensing deal for Arvinas’ cancer drug worth up to $1.01 billion

Under the agreement, Novartis has acquired global rights to develop and commercialize the drug, ARV-766, for an upfront payment of…

April 11, 2024 17:44 IST

mnc leaving india, Novartis AG, astera zeneca, opinion

Reduce the exits

Of late, however, there have been several instances of MNCs quitting India or scaling down their stake in their India…

February 24, 2024 04:00 IST

Novartis to acquire MorphoSys AG to strengthen oncology pipeline

Pelabresib is also being studied in patients with essential thrombocythemia (ET), which is currently in Phase 2 in second line…

February 6, 2024 08:53 IST

Novartis, cancer, GI cancer, GI tumour, healthcare news, pharma news,

Novartis’ innovative drug shows significant positive outcomes in Phase III trial for patients with gastrointestinal cancers

Data were presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.

January 22, 2024 12:23 IST

Novartis, mergers and acquisition, Cytokinetics, healthcare news, pharma news,

Novartis in advanced talks to buy Cytokinetics: Report

Vontobel pharmaceuticals analyst Stefan Schneider said a deal made sense for Novartis, with Cytokinetics active in the cardiovascular field, one…

January 9, 2024 16:58 IST

Novartis, Novartis news, innovative drugs, chronic myeloid leukemia, healthcare news, pharma news,

Novartis’ drug shows positive outcomes in Phase III trial for chronic myeloid leukemia treatment

Details will be presented at an upcoming medical conference and included as part of regulatory submissions in 2024

January 8, 2024 12:25 IST

Novartis, USFDA, oral monotherapy, Fabhalta, healthcare news, pharma news,

USFDA gives nod to Novartis’ oral monotherapy to treat rare blood disorder

Up to 88 percent of patients on anti-C5 treatment may have persistent anemia with over one-third of those patients requiring…

December 6, 2023 12:20 IST

Related News

New Zealand visa application, visa police certificates, visa Regional Passport Office, Indian Ministry of External Affairs, Immigration New Zealand

New Zealand issues new rules for Indian national visa applicants

Govt extended ITR AY 2025-26 deadline, but only 4.56 crore returns filed so far

China exits Pakistan’s $60 billion CPEC flagship project; Islamabad turns to ADB for funding

China exits Pakistan’s $60 billion economic corridor project; Islamabad turns to ADB for funding

Bigg Boss 19 contestant net worth: Bigg Boss 19 has been entertaining audiences with its high-energy episodes and stellar line-up of contestants. The list includes Gaurav Khanna, Ashnoor Kaur, Amaal Mallik, Tanya Mittal, Zeishan Quadri, Kunickaa Sadanand, Awez Darbar, and Abhishek Bajaj.

Bigg Boss 19: Check net worth of Tanya Mittal, Amaal Mallik, Gaurav Khanna, Ashnoor Kaur, and others

Françoise Bettencourt Meyers, the 72-year-old French beauty heiress and granddaughter of L’Oréal founder Eugène Schueller, has added about $24 billion to her fortune this year, making her wealthier.

Beauty Billionaire: Heiress gains $24 billion in 2025, overtakes Asia’s richest person Mukesh Ambani

HONOR X9C: AI features are a big draw

Life3 hr ago

The Honor X9c 5G smartphone showcases the power of AI in mid-range devices with its Qualcomm Snapdragon 6 Gen 1 processor and MagicOS 8.0. It also features a 108MP OIS Motion Sensing Camera and a 6600mAh silicon-carbon battery for extended battery life and fast charging. With its tough build and innovative hardware, the Honor X9c stands out from the crowd and delivers a seamless user experience.

View all shorts